Skip to content

Beta Bionics

US · BBNX #3406 by market cap Listed 2025
18.08 -0.55 -2.95%
Live - 5344 symbols - heartbeat 293s ago · 2026-10-08 09:16
Pre-market 17.85 -1.27%
After-hours 18.08 0.00%
Market cap
813.41M
P/B
3.17
EPS
-1.65
Reader sentiment Are you bullish or bearish on BBNX?

Anonymous reader poll. Unscientific, not investment advice.

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
  • Total institutional ownership fell 22.0 percentage points.

Institutional ownership

Held by institutions
101.32% -21.98pp
Institutions
173 +1
As of
2026/Q3 vs. prior period

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Holder types

Hedge Fund37.89%
Mutual Fund35.03%
VC/PE Fund16.25%
Public Company10.40%
Individual/Insider4.40%
Government Pension Fund0.83%
Sovereign Wealth Fund0.37%
Private Company0.30%
Insurance Company0.17%

Top holders as of 2026-06-30

Eventide Asset Management, LLC 11.88% · 6.25M sh
Soleus Capital Management, L.P. 8.35% · 4.39M sh
Morgan Stanley 8.02% · 4.22M sh
Sands Capital Alternatives, LLC 7.04% · 3.71M sh
BlackRock 6.35% · 3.34M sh
Divisadero Street Capital Management, LP 5.84% · 3.07M sh
Soleus Capital LLC 5.12% · 2.70M sh
Point72 Asset Management, L.P. 4.28% · 2.25M sh
Vanguard Capital Management, LLC 3.89% · 2.05M sh
Vestal Point Capital, LP 3.04% · 1.60M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 20 buys · 30 sells

NameRoleStake
Sean Saint Chief Executive Officer 0.76%
Mike Mensinger Chief Product Officer 0.34%
Steven Russell Chief Medical Officer 0.32%
Stephen Feider Chief Financial Officer 0.30%
Mark Hopman Chief Commercial Officer 0.11%
Maria Palasis Independent Director 0.06%
Adam Lezack Independent Director 0.05%
Gerard Michel Independent Director 0.02%
Sean Carney Independent Director 0.02%
Daniel Dearen Independent Director 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-30 Mark Hopman Chief Commercial Officer Automatic Disposition -370 $18.96
2026-09-21 Christina Jones Independent Director Automatic Disposition -6,430 $23.00
2026-09-15 Mark Hopman Chief Commercial Officer Automatic Disposition -30,779 $20.13
2026-09-15 Mike Mensinger Chief Product Officer Automatic Disposition -2,650 $22.00
2026-09-13 Mark Hopman Chief Commercial Officer Automatic Disposition -775 $15.52
2026-09-08 Mark Hopman Chief Commercial Officer Open Market Disposition -35,994 $18.46
2026-09-02 Sean Saint Chief Executive Officer Automatic Disposition -5,641 $20.08
2026-09-01 Sean Saint Chief Executive Officer Open Market Disposition -16,867 $19.11
2026-09-01 Stephen Feider Chief Financial Officer Open Market Disposition -6,675 $19.11
2026-09-01 Steven Russell Chief Medical Officer Open Market Disposition -4,221 $19.11
2026-09-01 Mark Hopman Chief Commercial Officer Open Market Disposition -5,327 $19.11
2026-09-01 Mike Mensinger Chief Product Officer Open Market Disposition -4,375 $19.11
2026-06-28 Stephen Feider Chief Financial Officer Derivative Exercise and Sale -10,000 $5.10–17.05
2026-06-23 Christina Jones Independent Director Automatic Disposition -1,406 $15.00
2026-06-23 Mark Hopman Chief Commercial Officer Automatic Disposition -1,258 $15.01
2026-06-03 Christina Jones Independent Director Automatic Disposition -2,811 $14.00
2026-06-03 Mark Hopman Chief Commercial Officer Automatic Disposition -275 $12.31
2026-06-01 Sean Saint Chief Executive Officer Open Market Disposition -16,872 $12.61
2026-06-01 Stephen Feider Chief Financial Officer Open Market Disposition -6,676 $12.61
2026-06-01 Steven Russell Chief Medical Officer Open Market Disposition -4,222 $12.61

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-10-08 09:16:15 · For reference only, not investment advice and not tailored to your situation.